SPY366.79+0.77 0.21%
DIA299.18+0.74 0.25%
IXIC12,349.37-5.74 -0.05%

UPDATE: Boston Scientific Says Decision Is Expected To Result In Pre-Tax GAAP Charges $225M-$300M, Exit Charges $100M-$150M, Will Be Accretive To EPS In 2021

This decision is expected to result in estimated total pre-tax GAAP charges of approximately $225 million to $300 million due to inventory, fixed asset, intangible asset and certain other exit charges and approximately

· 11/17/2020 06:08

This decision is expected to result in estimated total pre-tax GAAP charges of approximately $225 million to $300 million due to inventory, fixed asset, intangible asset and certain other exit charges and approximately $100 million to $150 million of these charges will impact the company's adjusted results. The vast majority of these charges will be recorded during the fourth quarter of 2020. The decision is expected to be accretive to GAAP and adjusted earnings per share in 2021 by approximately one to two cents and neutral thereafter.